aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Adze Biotechnology, founded with the mission to revolutionize cancer treatment, focuses on developing advanced oncolytic immunotherapies and PD-L1 decoy proteins. Their core vision is to create systemically deliverable treatments that not only target solid tumors but also engage the patient's immune system to foster robust and durable anti-tumor responses. Adze Biotechnology's market focus is on providing innovative solutions for advanced cancer treatment, aiming to improve patient outcomes significantly.
Notable figures affiliated with Adze Biotechnology include leading scientists and oncologists who specialize in immunotherapy and cancer research. The company has garnered attention from prominent investors in the biotech sector, reflecting confidence in its groundbreaking approach. Key achievements include the development of a versatile platform for oncolytic immunotherapies that has shown promising preclinical results. Adze Biotechnology's impact lies in its potential to transform cancer treatment paradigms, offering hope for more effective and lasting cancer therapies.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Cancer Treatment
Technology
Biotech
Tags
Healthtech
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Adze Biotechnology founded?
Adze Biotechnology was founded in 2019.
Where is Adze Biotechnology’s headquarters located?
Adze Biotechnology’s headquarters is located in Coral Gables, FL, US.
When was Adze Biotechnology’s last funding round?
Adze Biotechnology’s most recent funding round was for $6.1M (USD) in March 2023.
How many employees does Adze Biotechnology have?
Adze Biotechnology has 6 employees as of Feb 5, 2024.
How much has Adze Biotechnology raised to-date?
As of July 05, 2023, Adze Biotechnology has raised a total of $6.1M (USD) since Mar 14, 2023.
Add Comparison
Total Raised to Date
$6.1M
USD
Last Update Mar 14, 2023
Last Deal Details
$6.1M
USD
Mar 14, 2023
Series Unknown
Total Employees Over Time
6
As of Feb 2024
Adze Biotechnology Address
2332 Galiano St
2nd Floor
Coral Gables,
Florida
33134
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts